Generate Biomedicines, Inc.

Healthcare · Biotechnology · United States

Last price 14.46 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.86B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it...